Stay updated on Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check32 days agoNo Change Detected
- Check40 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check47 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check61 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check68 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.2%
- Check90 days agoChange DetectedA new Phase I/Ib study of Pembrolizumab in combination with Guadecitabine and Mocetinostat for advanced lung cancer has been added, replacing an earlier version of the same study that was last updated in August 2024.SummaryDifference1%
Stay in the know with updates to Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Epigenetic Drugs in Lung Cancer Clinical Trial page.